Anne-Laure Martin is an expert in Oncology at Unicancer (France). Anne-Laure Martin has authored 161 publications, the most recent in 2025, and is an investigator in 9 clinical trials. SLR score: 465 (community average: 125). How the SLR is computed.

LeadR Profile

Anne-Laure Martin Unicancer France
465 ScienceLeadR Reputation 465
Network Map

Oncology

Subspecialties: Dermatology - Public Health - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026

Source: PubMed

Unicancer

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 161

Citations

Citations: 15 811 1st author: 1 Last author: 2 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
PMID 40845255 — epidermal growth factor, estrogens, growth, breast neoplasms, receptors, estrogen, neoplasms, receptors, growth factor, breast, therapeutics, landslides
J Clin Oncol Top journal20250
Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.
PMID 40900676 — cancer survivors, breast neoplasms, pain, neoplasms, drug therapy, breast, diagnosis, therapeutics, chemotherapy
J Natl Cancer Inst20250
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model.
PMID 39250750 — breast neoplasms, mental disorders, neoplasms, breast, diagnosis, behavioral symptoms
J Natl Cancer Inst20243
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort.
PMID 39612621 — breast neoplasms, neoplasms, drug therapy, hormones, chemotherapy, adjuvant, breast, therapeutics, chemotherapy
ESMO Open20240
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities.
PMID 39106085 — breast neoplasms, neoplasms, breast, metabolomics, therapeutics
Clin Cancer Res20242

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
N/A 1
Phase 2 1

By status:

Completed 8
Recruiting 1

By type:

Interventional 9

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 4

LeadR Networks

Main global connection map